Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years
Overall, erenumab treatment significantly reduced the burden of migraine, leading to improved quality of life for patients and their families over a treatment period of 2 years.
Authors
- Christoph J. Schankin (ORCID: https://orcid.org/0000-0003-4668-6098)
- Heiko Pohl (ORCID: https://orcid.org/0000-0002-2778-6790)
- Dragana Viceic
- Philippe Ryvlin (ORCID: https://orcid.org/0000-0001-7775-6576)
- Catherine Parzini
- Christian P. Kamm (ORCID: https://orcid.org/0000-0002-3906-0161)
- Andreas R. Gantenbein (ORCID: https://orcid.org/0000-0001-5686-0200)
- Chiara Zecca (ORCID: https://orcid.org/0000-0002-9990-3431)
- Michael E. Arzt (ORCID: https://orcid.org/0000-0002-3000-9351)
- Dominik Zieglgänsberger
- Monika Kulartz‐Schank
- R. Agosti
Institutions
- University of Bern (CH)
- Novartis (Switzerland) (CH)
- University Hospital of Bern (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Ente Ospedaliero Cantonale (CH)
- University Hospital of Zurich (CH)
- Luzerner Kantonsspital (CH)
- Stiftung für Forschung in Spätantike und Mittelalter HR. Sennhauser (CH)
- GastroZentrum Hirslanden Zürich (CH)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1111/head.14943
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Research Committee, Aristotle University of Thessaloniki